SubCon

Monthly Project Updates

Prolific Machines

Illuminating biology's limitless potential for a healthier, more sustainable tomorrow

SubCon Monthly Update January 16, 2026

Project Architect: Shahram

Project Manager: Will

Project Team: Noreen, Amritha, Ian

Required Reviewers: Vidar, Victor

Prolific Machines

Executive Summary – Project Overview

Sub-project	Molecule(s)	Objectives(s)	Start	End
Patent	1. Epcoritamab (4-chain bispecific)	Demonstrate subunit expression level regulation by light exposure modulation Pools necessary → SCC likely	Dec 2025	Sep 2026
Cinnamon (Radiant)	1. RSV IgG 2. RSV Multabody 3. HIV IgG 4. HIV MB1 (monosp.) 5. HIV MB2 (trispec.) 6. HIV MB3 (trispec.)	**POC – demonstrate in pools only:** • **Control of subunit ratios** using single wavelength • **Improved titer** via separation of growth + production • *Different molecules used to show where optogenetics can improve titer + ratios for increasing levels of complexity*	Jan 2026 (delayed 1 month due to Master Agreement negotiations)	Aug 2026
Raspberry	1. Raspberry molecule (3-chain bispecific)	**POC – demonstrate in pools only:** Control H_scFv heterodimer ratios	TBD (after POC 1 → ≥mid-March+	+ 7 mos. → (≥ Oct 2026)

High | Medium | Low

Executive Summary - Key **risks** - Risk Register

Risk	Potential impact on milestone/KR	Mitigation
Risk: Cloning vectors laid out within SOW may be challenging	**Low** 1-2 month delay, depending on complexity.	**Mitigation:** Would require re-designing cloning strategy based on failure mode
Risk: Cloning trispecific MB with single vector may be challenging		**Containment:** Would cancel this work stream if cloning is unsuccessful.
Risk: Positional effects within vector change subunit expression levels	**Low** Unlikely to be significant enough to require re-work based on signals from Radiant.	**Mitigation:** However, if the impact was significant, it would delay the project by two months – would require re-iterating vector design based on learnings.

Urgent | Needs Review | Inform | Upcoming

Executive Summary - Key **decisions** - Decision Log

Decision	Status	Proposal or Path Forward
Decision: Adding one vector design and associated pool with a single vector for one of the trispecific Multabodies	**Informed** Project team	**Inform:** Team is aligned on scope addition This should help increase the probability of improving titer for trispecific Multabody, which is most important to Radiant.
Decision: Opto system selection for Radiant vector designs	**Upcoming**	**Upcoming:** Planning to use Gavpo for Radiant because it is more de-risked. But the vector designs can interchangeably use Gavpo or Cry2. Final opto system will be selected based on upcoming Raspberry and MAM01 pool data.

Project Timeline



De-scoped/ Paused	Off Track	Blocked/ Delayed	Issue	On track	Planning stage	Done
De-scoped/ Paused	Off Track	Blocked/ Delayed	Issue	On track	Planning stage	Done

Company OKRs & Project Milestones

Company & Customer Objectives	Sub-Project (Molecule)	Project Milestones	Previous Status	Current Status
<u>Prolific OKRs</u> **Objective 3:** Demonstrate undeniable value to customers **Key Result 3.3:** Demonstrate optogenetic control of subunit expression ratio of 2 different bi- or multi-specific therapeutic protein formats, leading to an increase in correctly-assembled complexes compared to constitutive expression while reaching industry-relevant titers of >5 g/L titer	**Ratiometric Control Patent (Epcoritamab)**	First pool production run data	New	Feb 21
		First clone production run data	New	Apr 1
		Data due to legal team	New	Aug 30
		Final Patent filing due	New	Sep 30
	Radiant (HIV & RSV Multabodies)	First pool production run data (SDS-PAGE)	New	Apr 1
		Analytical characterization of first production run by Radiant	New	May 1
		Second pool production run full dataset	New	Jun 7
		Report due to Gates Foundation	New	Aug 15
	Raspberry (3-chain bispecific)	[TBD] Anticipated earliest possible start date	New	On Track

De-scoped/ Paused | Off track | Blocked/ Delayed | Issue | On track | Planning stage | Done

Upcoming Data/Deliverables - SubCon Data Deck

Deliverable	OKR/Milestone	Date & Status	Aligned Specifications/Requirements
Data: Epcoritamab - first pool production run data	**Customer Goal** intermediate step	~Feb 21	Initial 10 day fed-batch production run in 24 DWPs for 24 Epcoritamab pools. Data will be used to down-select pools for cloning on Beacon.
Data: Radiant - first pool production run data (SDS-PAGE only)	**Customer Goal** intermediate step	~Apr 1	Initial 10 day fed-batch production run in 24 DWPs for 24 Epcoritamab pools. This initial data from SDS page will provide early signal on success of light modulated subunit control and titer improvements for Multabodies. Radiant will provide further analytical data ~1 month later.

Upcoming handoffs/ Cross-deliverables

Deliverable	Producer/Recipient	Date & Status	Aligned Specifications/Requirements
Deliverable: Analytical methods and reference material for in-house high-level characterization of Multabodies.	**To:** Prolific **From:** Radiant	Feb 1	Radiant will provide Prolific with assay methods and reference material for SDS-PAGE assay protocol they have developed.
Deliverable: Ship HCCF to Radiant for analytical characterization.	**To:** Radiant **From:** Prolific	Apr 1	Ship frozen harvested cell culture fluid (HCCF) to Radiant for analytical characterization.
Deliverable: Handoff Epcoritamab samples to AnChem for method development and titer measurement.	**To:** AnChem **From:** SubCon	Ongoing	24-48 samples from pool production runs. >250 µg of material to be delivered. If concentration is <1 mg/mL, AnChem will do purification. AnChem will use existing methods for titer and SEC.